Cargando…

Could Renin-Angiotensin System Inhibitors Be Protective From Severe COVID-19?

Detalles Bibliográficos
Autor principal:	Carey, Robert M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884239/ https://www.ncbi.nlm.nih.gov/pubmed/33566689 http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.16800

Ejemplares similares

Renin–angiotensin system inhibitors and mortality in patients with COVID-19
por: Rossi, Luca, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
por: Reynolds, Harmony R., et al.
Publicado: (2020)

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020)

Relation Between Renin–Angiotensin–Aldosterone System Inhibitors and COVID-19 Severity
por: Alhaddad, Mousa J, et al.
Publicado: (2022)

Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
por: Loader, Jordan, et al.
Publicado: (2021)

Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity
por: Gonçalves, Jorge, et al.
Publicado: (2023)

Renin-angiotensin system inhibitors in hospitalised patients with COVID-19
por: Williams, Bryan
Publicado: (2021)

Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts
por: Mahajan, Kunal, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19
por: Matsuzawa, Yasushi, et al.
Publicado: (2022)

Renin-angiotensin-aldosterone system inhibitors and the COVID-19 epidemic
por: Silva-Cardoso, José, et al.
Publicado: (2022)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Safety and Efficacy of Renin–Angiotensin–Aldosterone System Inhibitors in COVID-19 Population
por: Sattar, Yasar, et al.
Publicado: (2021)

COVID-19 and the Renin-Angiotensin System
por: Malha, Line, et al.
Publicado: (2020)

The systemic renin-angiotensin system in COVID-19
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2022)

Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update
por: Shukla, Ashwin Kumar, et al.
Publicado: (2021)

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
por: Golpe, Rafael, et al.
Publicado: (2020)

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
por: Golpe, Rafael, et al.
Publicado: (2020)

Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review
por: Ferrari, Filipe, et al.
Publicado: (2021)

Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19
por: Sackin, Henry
Publicado: (2021)

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
por: Tsampasian, Vasiliki, et al.
Publicado: (2022)

Chronotherapy with a Renin-angiotensin System Inhibitor Ameliorates Renal Damage by Suppressing Intrarenal Renin-angiotensin System Activation
por: Aoki, Taro, et al.
Publicado: (2020)

Commentary to Angiotensin-Converting-Enzyme 2 and Renin–Angiotensin System Inhibitors in COVID-19: An Update
por: Ferri, Claudio, et al.
Publicado: (2021)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

High Renin Concentrations in Severe COVID-19 Are Indicative for a Hypo–Renin–Angiotensin-System State
por: Akin, Sakir, et al.
Publicado: (2022)

COVID-19, Renin-Angiotensin System, and Hematopoiesis
por: Çiftçiler, Rafiye, et al.
Publicado: (2020)

The renin angiotensin aldosterone system and COVID-19
por: Alsufyani, Hadeel A., et al.
Publicado: (2020)

Renin Angiotensin System and COVID-19 Infection
por: Ferrara, Francesco, et al.
Publicado: (2022)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Severe food restriction activates the central renin angiotensin system
por: De Souza, Aline Maria Arlindo, et al.
Publicado: (2020)

Renin–angiotensin system inhibitors and COVID-19: overwhelming evidence against an association
por: de Abajo, Francisco J
Publicado: (2021)

Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea
por: Park, Jungchan, et al.
Publicado: (2021)

Is there enough evidence to discontinue the renin-angiotensin system inhibitors in patients with COVID-19?
por: Bobkova, Irina, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study
por: Dublin, Sascha, et al.
Publicado: (2020)

Could patients with chronic obstructive pulmonary disease benefit from renin angiotensin system inhibitors? A meta-analysis
por: Lv, Hongzhen, et al.
Publicado: (2023)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Renin–angiotensin system blockade in the COVID-19 pandemic
por: Cohen, Jordana B, et al.
Publicado: (2021)

Covid-19: the renin–angiotensin system imbalance hypothesis
por: Lanza, Katharina, et al.
Publicado: (2020)

Mortality and Pre‐Hospitalization use of Renin‐Angiotensin System Inhibitors in Hypertensive COVID‐19 Patients
por: Chen, Chen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1pk2kgeemm6iof5fseo9b25s1q